

PATENT

Case Docket No. DECLE26.001C1

Date: April 5, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Rousseau, et al.  
Appl. No. : 10/802,089  
Filed : March 16, 2004  
For : PHARMACEUTICAL  
COMPOSITION FOR  
TREATING OR PREVENTING  
DIABETES OR CANCER, OR  
THE WAARDENBURG  
SYNDROME  
Examiner : Unknown  
Group Art Unit : Unknown

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

April 5, 2004

(Date)

*Che S. Chereskin*

Che Swyden Chereskin, Ph.D., Reg. No. 41,466

TRANSMITTAL LETTER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- ( X ) An Information Disclosure Statement.
- ( X ) A PTO Form 1449 citing eleven (11) references (not included).
- ( X ) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- ( X ) Return prepaid postcard.

*Che S. Chereskin*


Che Swyden Chereskin, Ph.D.

Registration No. 41,466

Agent of Record

Customer No. 20,995

(949) 760-0404



Docket No.: DECLE26,001C1

Customer No. 20,995

### INFORMATION DISCLOSURE STATEMENT

Applicant : Rousseau, et al.  
App. No. : 10/802,089  
Filed : March 16, 2004  
For : PHARMACEUTICAL COMPOSITION  
FOR TREATING OR PREVENTING  
DIABETES OR CANCER, OR THE  
WAARDENBURG SYNDROME  
Examiner : Unknown  
Group Art Unit : Unknown

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing 11 references that are of record in U.S. patent application No. 09/763,535, filed July 2, 2001, which is the parent of this continuation application, and is relied upon for an earlier filing date under 35 U.S.C. § 120. Copies of the references are not submitted pursuant to 37 C.F.R. § 1.98(d).

This Information Disclosure Statement is being filed within three months of the filing date of this application and no fee is required in accordance with 37 C.F.R. § 1.97(b)(1), (b)(2), or (b)(4).

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: April 5, 2004

By: Che S. Chereskin  
Che Swyden Chereskin, Ph.D.  
Registration No. 41,466  
Agent of Record  
Customer No. 20,995  
(949) 760-0404

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
DECL26.001C1APPLICATION NO.  
10/802,089INFORMATION DISCLOSURE STATEMENT  
BY APPLICANTAPPLICANT  
Rousseau, et al.FILING DATE  
March 16, 2004GROUP  
Unknown

(USE SEVERAL SHEETS IF NECESSARY)

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 98/11254	03/19/98	WIPO				

EXAMINER  
INITIAL

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

	Landry, et al. "HNF-6 is Expressed in Endoderm Derivatives and Nervous System of the Mouse Embryo and Participates to the Cross-Regulatory Network of Liver-Enriched Transcription Factors," <i>Developmental Biology</i> , Vol. 192, pp. 247-257, December 15, 1997
	Lannoy, et al. "Isoforms of Hepatocyte Nuclear Factor-6 Differ in DNA-Binding Properties, Contain a Bifunctional Homeodomain, and Define the New ONECUT Class of Homeodomain Proteins," <i>The Journal of Biological Chemistry</i> , Vol. 273, No. 22, pp. 13552-13562, May 29, 1998.
	Rausa, et al., "The Cut-Homeodomain Transcriptional Activator HNF-6 is Coexpressed with Its Target Gene HNF 3 $\beta$ in the Developing Murine Liver and Pancreas," <i>Developmental Biology</i> , Vol. 192, pp. 228-246, December 15, 1997.
	Spek, et al. "Type I Protein C Deficiency Caused by Disruption of a Hepatocyte Nuclear Factor (HNF)-6/HNF-1 Binding Site in the Human Protein C Gene Promoter," <i>The Journal of Biological Chemistry</i> , Vol. 273, No. 17, pp. 10168-10173, April 24, 1998.
	Vaisse, et al., "Pancreatic Islet Expression Studies and Polymorphic DNA Markers in the Genes Encoding Hepatocyte Nuclear Factor-3 $\alpha$ , -3 $\beta$ , -3 $\gamma$ , -4 $\gamma$ and -6," <i>Diabetes</i> , Vol. 46, No. 8, pp. 1364-1367, August, 1997.
	Jacquemin, et al. "OC-2, a Novel Mammalian member of the ONECUT Class of Homeodomain Transcription Factors Whose Function in Liver Partially Overlaps with that of Hepatocyte Nuclear Factor-6," <i>Journal of Biological Chemistry</i> , Vol. 274, No. 5, pp. 2665-2671, January 29, 1999.
	Lemaigre, et al., "Hepatocyte Nuclear Factor 6, a Transcription Factor that Contains a Novel Type of Homeodomain and a Single Cut Domain," <i>Proceedings of the National Academy of Sciences</i> , Vol. 93, pp. 9460-9464, 1996.
	Sigmund. "Viewpoint: Are Studies in Genetically Altered Mice Out of Control?" <i>Arteriosclerosis, Thrombosis and Vascular Biology</i> , Vol. 20, pp. 1425-1429, 2000.
	Vanhorenbeeck, et al. "OC-3, a Novel Mammalian Member of the ONECUT Class of Transcription Factors," <i>Biochemical and Biophysical Research Communications</i> , Vol. 292, pp. 848-854, 2002.
	Jacquemin, et al. "The Transcription Factor ONECUT-2 Controls the Microphthalmia-Associated Transcription Factor Gene," <i>Biochemical and Biophysical Research Communications</i> , Vol. 285, pp. 1200-1205, 2001.

H:\DOCS\CSC\CSC-6846.DOC  
033104

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.